Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment

L. Priano, G. Albani, A. Brioschi, G. Guastamacchia, S. Calderoni, L. Lopiano, M. Rizzone, R. Cavalli, M. R. Gasco, F. Fraschini, B. Bergamasco, A. Mauro

Research output: Contribution to journalArticle

Abstract

This study analyzed the macrostructure and microstructure of sleep in 12 parkinsonian patients under basal conditions (T0) and during 1-night treatment (T1) with a new formulation of apomorphine. This new formulation consisted in a microemulsion of apomorphine administered by the transdermal route, able to provide a constant release of the drug over several hours (APO-TD). Sleep analysis at T1 compared with T0 revealed a 16% increment of total sleep time, a 12% increment of sleep efficiency, a 16% increment of stage 3 and 4 non-REM sleep, a 15% reduction of periodic limb movements index, a 22% reduction of arousal index, and a 23% reduction of cycling alternating patterns/non-REM. We conclude that APO-TD may be able to reduce nocturnal anomalous movements, akinesia, and rigidity in Parkinson's disease, and may reduce the disturbed sleep typical of Parkinson's disease.

Original languageEnglish
Pages (from-to)207-208
Number of pages2
JournalNeurological Sciences
Volume24
Issue number3
DOIs
Publication statusPublished - Oct 2003

Fingerprint

Apomorphine
Sleep
Parkinson Disease
Therapeutics
Sleep Stages
Arousal
Extremities

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. / Priano, L.; Albani, G.; Brioschi, A.; Guastamacchia, G.; Calderoni, S.; Lopiano, L.; Rizzone, M.; Cavalli, R.; Gasco, M. R.; Fraschini, F.; Bergamasco, B.; Mauro, A.

In: Neurological Sciences, Vol. 24, No. 3, 10.2003, p. 207-208.

Research output: Contribution to journalArticle

Priano, L. ; Albani, G. ; Brioschi, A. ; Guastamacchia, G. ; Calderoni, S. ; Lopiano, L. ; Rizzone, M. ; Cavalli, R. ; Gasco, M. R. ; Fraschini, F. ; Bergamasco, B. ; Mauro, A. / Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. In: Neurological Sciences. 2003 ; Vol. 24, No. 3. pp. 207-208.
@article{caf16d6e078a47c58b63df540cb268b2,
title = "Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment",
abstract = "This study analyzed the macrostructure and microstructure of sleep in 12 parkinsonian patients under basal conditions (T0) and during 1-night treatment (T1) with a new formulation of apomorphine. This new formulation consisted in a microemulsion of apomorphine administered by the transdermal route, able to provide a constant release of the drug over several hours (APO-TD). Sleep analysis at T1 compared with T0 revealed a 16{\%} increment of total sleep time, a 12{\%} increment of sleep efficiency, a 16{\%} increment of stage 3 and 4 non-REM sleep, a 15{\%} reduction of periodic limb movements index, a 22{\%} reduction of arousal index, and a 23{\%} reduction of cycling alternating patterns/non-REM. We conclude that APO-TD may be able to reduce nocturnal anomalous movements, akinesia, and rigidity in Parkinson's disease, and may reduce the disturbed sleep typical of Parkinson's disease.",
author = "L. Priano and G. Albani and A. Brioschi and G. Guastamacchia and S. Calderoni and L. Lopiano and M. Rizzone and R. Cavalli and Gasco, {M. R.} and F. Fraschini and B. Bergamasco and A. Mauro",
year = "2003",
month = "10",
doi = "10.1007/s10072-003-0133-z",
language = "English",
volume = "24",
pages = "207--208",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",

}

TY - JOUR

T1 - Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment

AU - Priano, L.

AU - Albani, G.

AU - Brioschi, A.

AU - Guastamacchia, G.

AU - Calderoni, S.

AU - Lopiano, L.

AU - Rizzone, M.

AU - Cavalli, R.

AU - Gasco, M. R.

AU - Fraschini, F.

AU - Bergamasco, B.

AU - Mauro, A.

PY - 2003/10

Y1 - 2003/10

N2 - This study analyzed the macrostructure and microstructure of sleep in 12 parkinsonian patients under basal conditions (T0) and during 1-night treatment (T1) with a new formulation of apomorphine. This new formulation consisted in a microemulsion of apomorphine administered by the transdermal route, able to provide a constant release of the drug over several hours (APO-TD). Sleep analysis at T1 compared with T0 revealed a 16% increment of total sleep time, a 12% increment of sleep efficiency, a 16% increment of stage 3 and 4 non-REM sleep, a 15% reduction of periodic limb movements index, a 22% reduction of arousal index, and a 23% reduction of cycling alternating patterns/non-REM. We conclude that APO-TD may be able to reduce nocturnal anomalous movements, akinesia, and rigidity in Parkinson's disease, and may reduce the disturbed sleep typical of Parkinson's disease.

AB - This study analyzed the macrostructure and microstructure of sleep in 12 parkinsonian patients under basal conditions (T0) and during 1-night treatment (T1) with a new formulation of apomorphine. This new formulation consisted in a microemulsion of apomorphine administered by the transdermal route, able to provide a constant release of the drug over several hours (APO-TD). Sleep analysis at T1 compared with T0 revealed a 16% increment of total sleep time, a 12% increment of sleep efficiency, a 16% increment of stage 3 and 4 non-REM sleep, a 15% reduction of periodic limb movements index, a 22% reduction of arousal index, and a 23% reduction of cycling alternating patterns/non-REM. We conclude that APO-TD may be able to reduce nocturnal anomalous movements, akinesia, and rigidity in Parkinson's disease, and may reduce the disturbed sleep typical of Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=0142217526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142217526&partnerID=8YFLogxK

U2 - 10.1007/s10072-003-0133-z

DO - 10.1007/s10072-003-0133-z

M3 - Article

C2 - 14598090

AN - SCOPUS:0142217526

VL - 24

SP - 207

EP - 208

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 3

ER -